TD Cowen Issues Pessimistic Forecast for Bruker (NASDAQ:BRKR) Stock Price

Bruker (NASDAQ:BRKR) had its price target lowered by analysts at TD Cowen from $53.00 to $43.00 in a note issued to investors on Friday,Benzinga reports. The firm currently has a “hold” rating on the medical research company’s stock. TD Cowen’s price objective would indicate a potential upside of 15.85% from the company’s previous close.

A number of other research firms also recently issued reports on BRKR. Barclays dropped their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday. Weiss Ratings reiterated a “sell (d+)” rating on shares of Bruker in a research note on Monday, December 29th. Rothschild & Co Redburn set a $60.00 price objective on shares of Bruker in a research report on Thursday, November 20th. Wells Fargo & Company boosted their price objective on Bruker from $48.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Finally, Wolfe Research raised shares of Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 target price on the stock in a report on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Bruker has an average rating of “Hold” and an average target price of $50.92.

Bruker Stock Performance

NASDAQ BRKR traded down $0.39 during trading hours on Friday, hitting $37.12. The company’s stock had a trading volume of 926,901 shares, compared to its average volume of 2,613,844. Bruker has a 12 month low of $28.53 and a 12 month high of $56.22. The company’s 50 day simple moving average is $47.15 and its two-hundred day simple moving average is $40.55. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.85 and a quick ratio of 0.91. The company has a market cap of $5.64 billion, a P/E ratio of -232.06, a price-to-earnings-growth ratio of 5.58 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.61% and a positive return on equity of 15.45%. The company had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. During the same period in the previous year, the business earned $0.76 EPS. The business’s revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts expect that Bruker will post 2.69 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $49.20, for a total value of $98,400.00. Following the completion of the sale, the vice president directly owned 128,443 shares in the company, valued at $6,319,395.60. This trade represents a 1.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. State Street Corp grew its stake in Bruker by 2.5% in the 4th quarter. State Street Corp now owns 3,831,814 shares of the medical research company’s stock worth $180,700,000 after acquiring an additional 91,706 shares in the last quarter. Royal London Asset Management Ltd. lifted its holdings in shares of Bruker by 1.5% in the 4th quarter. Royal London Asset Management Ltd. now owns 788,344 shares of the medical research company’s stock worth $37,139,000 after buying an additional 11,543 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Bruker by 1.8% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 272,697 shares of the medical research company’s stock worth $12,847,000 after buying an additional 4,772 shares in the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Bruker by 17.0% in the fourth quarter. Quadrant Capital Group LLC now owns 7,177 shares of the medical research company’s stock valued at $338,000 after acquiring an additional 1,044 shares in the last quarter. Finally, CI Investments Inc. lifted its stake in Bruker by 95.6% in the fourth quarter. CI Investments Inc. now owns 254,770 shares of the medical research company’s stock worth $12,002,000 after acquiring an additional 124,537 shares during the period. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Key Headlines Impacting Bruker

Here are the key news stories impacting Bruker this week:

• Positive Sentiment: Revenue beat: Q4 revenue came in at $977.2M versus consensus ~$964.6M, showing top-line resilience. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: FY-2026 revenue guidance raised/firm: Bruker guided to roughly $3.6B in revenue for FY-2026, above street revenue expectations, which supports growth visibility. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Strategic partnership: Premas Life Sciences partnership to expand Bruker Spatial Biology in India may help regional commercialization and addressable market. Premas Life Sciences Partners with Bruker Spatial Biology
• Neutral Sentiment: Market commentary and previews: Multiple outlets published earnings previews and metric analyses; useful for context but not a direct catalyst. Bruker Q4 2025 Earnings Preview
• Neutral Sentiment: Short-interest data appears to be a reporting glitch (entries show 0 shares / NaN changes); not a confirmed short squeeze or wave of new shorts. (Data sources repeated reporting zero).
• Negative Sentiment: EPS miss and profitability weakness: Q4 EPS was $0.59 vs. consensus $0.65 and down from $0.76 year‑ago; net margin was negative (−0.61%), signaling margin pressure. Bruker (BRKR) Q4 Earnings Miss Estimates
• Negative Sentiment: EPS guidance mixed: FY-2026 EPS guidance of $2.10–$2.15 is roughly in line with, but slightly below, some expectations (consensus ~2.13) and may disappoint investors focused on near-term earnings growth. Bruker Reports Fourth Quarter and Full Year 2025 Financial Results

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.